ClinicalTrials.gg
RecruitingNCT06192407Updated Nov 4, 2026

Fatty Acid Modulation of Brain Function in Older Adults

An interventional study of High Oleic Acid Diet and High Palmitic Acid Diet in Aging, sponsored by University of Vermont. Recruiting at 1 site in United States. Open to participants aged 65 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of Vermont · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
65 Years to 75 Years
Sex
All
01

Study summary

In this crossover study, the investigtors will administer two experimental diets in a random order for one week, and each experimental diet will be preceded by a one-week, low fat control diet for a total four-week study period. The goal is to study how the fatty acid content of the diet affects brain functioning in healthy adults aged 65-75 years. One experimental diet will have a high palmitic acid (PA)/oleic acid (OA) ratio (HPA), typical of the North American diet. The other experimental diet will have a low PA/OA ratio (HOA), typical of the Mediterranean Diet. All allowed food and drink (except water) will be provided by the investigative team, and compliance will be enhanced by constant, intense dietary surveillance by a registered dietitian.

Read the detailed description

This study will examine how manipulating dietary fatty acids affects brain functioning in older adults. Prior studies have shown that there are behavioral changes that can be made to improve cognition in adults on an acute time scale including improving sleep and physical activity. Based on preclinical data and prior studies in humans the investigators propose that brain functioning also can be acutely improved with a reduction in dietary saturated fat. This approach will first be used in cognitively normal older adults without dementia, but in the future it may be that improving baseline cognition is beneficial in patients with mild cognitive impairment and Alzheimer's disease even if the overall course of the patient's neurological condition is increasingly impaired cognitive function.

The investigators will manipulate the dietary ratios of palmitic acid (PA) and oleic acid (OA), which are the most prevalent saturated and monounsaturated fatty acids, respectively in the diet and body lipids. Using a crossover study of men and women, aged 65-75 years, the investigators will administer two experimental diets in a random order for one week and each experimental diet will be preceded by a one-week, low fat control diet for a four-week total study period. One experimental diet will have a high PA/OA ratio typical of the usual North American Diet and the other experimental diet will have a low PA/OA ratio typical of the Mediterranean Diet. The following primary outcomes will be assessed: working memory performance, activation of working memory networks using functional magnetic resonance imaging (fMRI) and functional connectivity.

The impact of this study is that these data may suggest one mechanism for acutely improving cognition in healthy older adults and potentially in those with cognitive impairment such as mild cognitive impairment and Alzheimer's disease. While changing dietary behavior long term requires additional investigation, there are potential immediate benefits to acute improvements in cognition on quality of life for older adults.

02

Conditions studied

  • Aging

Keywords

  • fatty acids
  • diet
  • aging
  • MRI
  • palmitic acid
  • oleic acid
03

In context

Lead sponsor

University of Vermont is the lead sponsor of 221 studies on the registry; 27 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 9 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women age range 65-75 years
  • Normal cognition (see Research Strategy for details on cognitive assessments)
  • "Healthy" ( (BMI) of 20-40 kg/m2)

Exclusion criteria

Exclusion Criteria:

  • Significant cognitive or behavioral impairment (see Research Strategy for testing and exclusions) or pharmacological treatment for this (e.g. antipsychotics, anxiolytics, and sedative medications).
  • Hormone replacement therapy, past 3 months.
  • Hyper-androgenic condition.
  • ≥7.5% and or Fasting plasma glucose concentration ≥130 mg/dL.
  • Type 2 Diabetes if receiving any other therapy than metformin.
  • Use of nicotine or ingestion of caffeine or alcohol during the study.
  • Habitual fat intake \< 25% of kcal or strict vegetarian diet.
  • Sleep apnea requiring continuous positive airway pressure at night.
  • Lung, cardiac (heart failure or its treatment), liver disease, renal disease, cancer, and any other medical disorder known or thought to cause inflammation or abnormalities of cognition
  • Actively training for an athletic event or participating in competitive sports (such as league play or tournaments)
  • Intolerance or allergy to any of the food provided in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    High Palmitic Acid Diet (HPA)

    Participants will ingest the HPA diet for one week. The saturated fatty acid will be high in palmitic acid which is the most prevalent saturated fatty acid in the American diet. The HPA diet will be proceeded by a one week controlled diet were the fat content is balanced between monounsaturated and saturated fatty acids.

    Dietary Supplement: High Palmitic Acid Diet

  • Experimental
    High Oleic Acid/Low Palmitic Acid Diet (HOA)

    Participants will ingest the HOA diet for one week. The monounsaturated fatty acid will be high in oleic acid which is the most prevalent monounsaturated fatty acid in the Mediterranean diet. The HOA diet will be proceeded by a one week controlled diet were the fat content is balanced between monounsaturated and saturated fatty acids.

    Dietary Supplement: High Oleic Acid Diet

Interventions

  • Dietary supplementHigh Oleic Acid Diet

    Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is 100% hazelnut oil. They will be taught to consume the oil with each meal and mix it in with the food provided.

    Also known as: HOA

  • Dietary supplementHigh Palmitic Acid Diet

    Subjects are provided with all food for each meal every day. The food is low in fat. In addition, subjects are provided with an oil mix that is palm oil-89%, peanut oil-6.75%, and virgin olive oil-4.25%; . They will be taught to consume the oil with each meal and mix it in with the food provided.

    Also known as: HPA

06

What researchers measure

Primary outcomes

  1. Working Memory Performance

    Accuracy for performance on the Nback working memory test during fMRI

    Time frame: after 7 days of each diet

  2. Working Memory Brain Activation

    Blood Oxygen Level Dependent (BOLD) activation during the Nback working memory test during fMRI

    Time frame: after 7 days of each diet

  3. Working Memory Brain Functional Connectivity

    BOLD functional connectivity during resting state fMRI

    Time frame: after 7 days of each diet

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be acquired from 50 adults aged 65-75. All data will be de-identified prior to receipt by the repository, but the information needed to generate a global unique identifier will be collected for each subject. The specific data types are: From Screening: demographic, standard medical laboratory screening tests such as serum lipid concentrations, neuropsychological test scores, dual x-ray absorptiometry (DEXA) measurements, blood leptin. From the each of the 4 Study Days: unprocessed MRI data, processed MRI Brain Imaging Data Structure (BIDS) images, serum lipid concentrations, raw data from the Actigraph, processed sleep and activity data from the Actigraph measurements, daily stressors assessment, mood assessment, cognitive test scores.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: All data will be deposited at the Image \& Data Archive (IDA) run by the Laboratory of Neuro Imaging (LONI) at the University of Southern California (USC) Mark and Mary Stevens Neuroimaging and Informatics Institute starting 12 months after the award begins and will be deposited every six months thereafter. The research community will have access to data when the award ends. Data collections can be created that contain the data used for every publication. The IDA will make decisions about how long to preserve the data, but that data archive has not deleted any deposited data up to now. Nevertheless, the investigators will maintain thier own archive of the data for at least three years after the project ends.

Access criteria: To request access to the data stored on the IDA, researchers will use the standard processes at the IDA which involves registering and creating an account. A data use application will be submitted along with the IDA registration and approved users will pe provided free access to the data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Jul 2028, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2023
First posted
Jan 5, 2024
StartActual
Apr 15, 2024
Primary completionEst.
Jul 30, 2028
CompletionEst.
Oct 31, 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, oversight details and contact details
1 update, last Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Minor edits only
    + 3 other changes: verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06192407
Responsible party
Julie Dumas (Professor, University of Vermont) — Principal investigator
First posted
Jan 5, 2024
Start date
Apr 15, 2024
Primary completion
Jul 30, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Julie Dumas, Ph.D.
Contact
julie.dumas@uvm.com
1(802)847-2523
Jenna Makarewicz, B.S.
Contact
jenna.makarewicz@uvmhealth.org
1(802)847-8248
Julie Dumas, Ph.D.
principal investigator · University of Vermont
Craig L Kien, MD, PhD
principal investigator · University of Vermont

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion